Abstract
Apoptosis is an important process in the development of the nervous system. Typically, ∼50% of the neurons apoptose during neurogenesis before the nervous system matures. However, recent paradigms implicate premature apoptosis and / or aberrations in the fine control of neuronal apoptosis in the pathogenesis of a variety of neurodegenerative disorders such as Alzheimers disease, Parkinsons disease, Huntingtons disease, amyotrophic lateral sclerosis, spinal muscular atrophy, stroke, brain trauma, spinal cord injury, and diabetic neuropathy. This review will focus on the current concepts salient to understanding the apoptosis death program, the mediators and control of cellular apoptosis, and the relationship between aberrant apoptosis and genesis of neurodegenerative disorders. The discussion will also highlight current advances in methodology, such as utilization of neuronal cell lines and mutant animal models, in investigations of neuronal apoptotic death. The knowledge of apoptosis mechanisms could underpin the basis for development of novel therapeutic strategies and treatment modalities that are directed at control of the neuronal apoptotic death program.
Keywords: neuronal apoptosis, apoptosis and neurodegeneration, mitochondrial apoptotic signaling, oxidative stress and apoptosis, apoptosis and cerebrovascular injury, cerebral ischemia/reperfusion
Current Neurovascular Research
Title: Apoptosis: A Key in Neurodegenerative Disorders
Volume: 1 Issue: 4
Author(s): Oleksandr Ekshyyan and Tak Yee Aw
Affiliation:
Keywords: neuronal apoptosis, apoptosis and neurodegeneration, mitochondrial apoptotic signaling, oxidative stress and apoptosis, apoptosis and cerebrovascular injury, cerebral ischemia/reperfusion
Abstract: Apoptosis is an important process in the development of the nervous system. Typically, ∼50% of the neurons apoptose during neurogenesis before the nervous system matures. However, recent paradigms implicate premature apoptosis and / or aberrations in the fine control of neuronal apoptosis in the pathogenesis of a variety of neurodegenerative disorders such as Alzheimers disease, Parkinsons disease, Huntingtons disease, amyotrophic lateral sclerosis, spinal muscular atrophy, stroke, brain trauma, spinal cord injury, and diabetic neuropathy. This review will focus on the current concepts salient to understanding the apoptosis death program, the mediators and control of cellular apoptosis, and the relationship between aberrant apoptosis and genesis of neurodegenerative disorders. The discussion will also highlight current advances in methodology, such as utilization of neuronal cell lines and mutant animal models, in investigations of neuronal apoptotic death. The knowledge of apoptosis mechanisms could underpin the basis for development of novel therapeutic strategies and treatment modalities that are directed at control of the neuronal apoptotic death program.
Export Options
About this article
Cite this article as:
Ekshyyan Oleksandr and Aw Yee Tak, Apoptosis: A Key in Neurodegenerative Disorders, Current Neurovascular Research 2004; 1 (4) . https://dx.doi.org/10.2174/1567202043362018
DOI https://dx.doi.org/10.2174/1567202043362018 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Roles of ID, IA and IK in the Electrophysiological Functions of Small-Diameter Rat Trigeminal Ganglion Neurons
Current Molecular Pharmacology Neuropeptides as Possible Targets in Sleep Disorders: Special Emphasis on Hypocretin-Deficient Narcolepsy
CNS & Neurological Disorders - Drug Targets Calpain and Its Involvement in the Pathophysiology of CNS Injuries and Diseases: Therapeutic Potential of Calpain Inhibitors for Prevention of Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Berberine Administration in Treatment of Colitis: A Review
Current Drug Targets Penumbra in Acute Ischemic Stroke
Current Neurovascular Research Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease
Current Pharmaceutical Biotechnology Emerging Signalling and Protein Interactions Mediated Via Metabotropic Glutamate Receptors
Current Drug Targets - CNS & Neurological Disorders Focus on the Role of Glutamate in the Pathology of the Peripheral Nervous System
CNS & Neurological Disorders - Drug Targets MiR-485-5p Promotes Neuron Survival through Mediating Rac1/Notch2 Signaling Pathway after Cerebral Ischemia/Reperfusion
Current Neurovascular Research The Association between Regular Cannabis Exposure and Alterations of Human Brain Morphology: An Updated Review of the Literature
Current Pharmaceutical Design Current Research on Opioid Receptor Function
Current Drug Targets A Central Role for ATP Signalling in Glial Interactions in the CNS
Current Drug Targets Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews Anticonvulsant and Antinociceptive Actions of Novel Adenosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Formulation and Characterization of Mucoadhesive Microparticles of Cinnarizine Hydrochloride Using Supercritical Fluid Technique
Current Drug Delivery Nocistatin: Milestone of One Decade of Research
Current Pharmaceutical Design Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Regenerative Potential of Stem Cell-derived Extracellular Vesicles in Spinal Cord Injury (SCI)
Current Stem Cell Research & Therapy The proNGF-p75NTR-Sortilin Signalling Complex as New Target for the Therapeutic Treatment of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Molecular Pathophysiology of Cavernous Nerve Injury and Identification of Strategies for Nerve Function Recovery After Radical Prostatectomy
Current Drug Targets